Patients with Crigler-Naijar syndrome (CN) type I inherit an autosomal recessive trait for hyperbilirubinemia, which is characterized by the total absence of bilirubin UDP-glucuronosyltransferase (transferase) activity. The (2, 3, 4 , and 5) specifying the 3' half of the transferase coding regions (codons 289-533) and the entire 3' untranslated region of each mRNA. This gene model predicts that a single critical mutation in any of these four "common"1 exons may inactivate the entire family of encoded transferases. In agreement with this prediction, we show here that in the first CN type I individual analyzed (patient F.B.), a 13-bp deletion has occurred in exon 2. Analysis of product generated by the polymerase chain reaction and genomic DNA demonstrated that F.B. is homozygous for the defective allele (UGTI*FB), and that the consanguineous parents are both heterozygotic at this locus. The mutation is predicted to result in the synthesis of severely truncated bilirubin transferase isozymes that are lacking a highly conserved sequence in the carboxyl-terminus and the characteristic membrane (endoplasmic reticulum)-anchoring segment ofthe protein molecule. (J. Clin.
Introduction
Bilirubin, a toxic metabolite formed by the ongoing turnover of hemoproteins (most significantly hemoglobin) is normally metabolized to excretable derivatives by conjugation of one or both ofthe carboxyl groups ofits propionyl side chains (C-8 or C-12) with glucuronic acid (1) . Both the formation of the C-8 or C-12 monoglucuronide or the C-8, C-12 diglucuronide is catalyzed by hepatic bilirubin UDP-glucuronosyltransferase (2) . Inadequate bilirubin glucuronidation, commonly observed in neonates (3), breast-fed infants (4) , and as a result of liver diseases (5) , is associated with the accumulation ofserum bilirubin and the appearance of the clinical features ofjaundice (3) . Coincident with the continuous and marked elevations (> 340 ,umol/liter) in serum bilirubin concentrations seen in serious diseased states is the risk of kernicterus, the degenerative changes associated with bilirubin deposition in the brain (3) . Milder elevations in the serum level ofthis heme derivative are seen in approximately half of all neonates, and are due to delays in the developmental onset ofbilirubin transferase activity normally occurring one to five days after birth. Although the short-term maintenance ofjaundiced neonates is a major concern ofpediatric clinicians, children with inborn errors in bilirubin glucuronidation (totally lacking this function) present an even greater challenge. In 1952, Crigler and Najjar (6) described a syndrome featuring chronic nonhemolytic unconjugated hyperbilirubinemia in which hepatic bilirubin UDPglucuronosyltransferase activity is absent. The disorder,
Crigler-Najjar syndrome (CN) 1 type I, is inherited in an autosomal recessive pattern (7) (8) (9) . The fatalities associated with this condition confirm the need to detoxify bilirubin. Therefore, the characterization of the bilirubin transferase gene is critical to making progress in the development oftherapies for the type I disease.
Recently, we reported the isolation and characterization of two human liver bilirubin UDP-glucuronosyltransferase cDNAs, HUG-BrI and HUG-Br2 (2) , which, upon expression individually in COS-1 cells, were both found to encode isoforms that catalyze the formation of the two bilirubin monoglucuronides and the diglucuronide. Northern analysis of HUG-Brl and HUG-Br2 mRNA showed that HUG-Brl is fourfold more abundant than HUG-Br2, and that in the Erythrocebus patas monkey, mRNA hybridizing with HUG-Br2 but not HUG-Brl is inducible by phenobarbital. We also showed (2) that mRNAs corresponding to both bilirubin transferase isoforms were present in the explanted liver ofa CN type I patient (not F.B.). The observations that the mRNAs were of the normal size (-2.6 kb) and abundance suggest that neither defective regulation nor gross abnormalities in gene structure is causative, and that smaller point mutations are probably involved.
In further studies, we isolated and determined the structure of an 85-kb locus (10) , UGTI, on chromosome 2 (11) , which encodes the two bilirubin UDP-glucuronosyltransferase isoforms. With this information, we began the search for mutations responsible for the lack ofdetectable bilirubin transferase activity in CN type I patients. Here we show that in the first affected individual studied in detail, a critical 1 3-bp deletion exists in exon 2 of the UGTI gene complex. The predicted effect of the mutation on the primary structure of the bilirubin transferase isoenzymes, together with our demonstration ofthe expected familial distribution of the defective allele, is described in this report.
Methods
CN type I human samples. Blood samples were collected from F.B., a 4-yr-old male CN type I patient, his parents, and A.R., an unrelated normal female. The patient is the 37-wk, 3,470-g offspring ofa consanguineous mating of Italian descent. All other immediate family members are clinically normal. Marked jaundice appeared at 12 d of age, and peak bilirubin (all unconjugated) was 598 Mmol/liter. Hemoglobin was 19.6 g%, and the reticulocyte count was 0.7%. The mother was 0 negative, and the baby was 0 positive, but direct and indirect Coombs' tests were negative. The results of the following studies were normal: urinary menthol glucuronides after oral administration (8) , transaminases, alkaline phosphatase, 5'-nucleotidase, total bile acids, thyroid functions tests, prothrombin time, partial thromboplastin time, glucose-6-phosphate-dehydrogenase screen, pyruvate kinase screen, a-antitrypsin levels, and various bacterial cultures. Unconjugated hyperbilirubinemia persisted despite repeated exchange transfusions, phototherapy, and administration of phenobarbital. A liver biopsy at 6 wk of age confirmed normal histology and the absence of bilirubin UDP-glucuronosyltransferase activity (12) . Bilirubin glucuronides were absent in duodenal bile, serum, and urine (13) . Treatment with whole body phototherapy (12 h/d) and cholestyramine (3 g/d) was initiated. Under this treatment regimen, bilirubin levels ranged between 300-450 ,mol/liter. At age 41/2 yr he showed normal somatic, intellectual, and neurological development.
Preparation oflymphocyte genomic DNA. The blood samples were transferred to 50-ml Falcon tubes and spun at 4,000 rpm for 30 min in an HS-4 rotor (Dupont Instruments-Sorvall Biomedical Div., Wilmington, DE). The pellet was resuspended in 40 ml ofprechilled buffer (10 mM Tris-Cl, pH 7.5, 10 mM NaCl, 3 mM MgCI, and 0.2% Triton X-100), recentrifuged, and the step was repeated a second time. The pellet was resuspended the final time in 2 ml of SDS solution (10 mM Tris-Cl, pH 7.5,20 mM NaCl, 5 mM MgCl, and 2% SDS). Proteinase K (900 ig/!10 ml vol blood) was added, and the tubes were incubated at 37°C for 2 h and then at room temperature overnight. The samples were then extracted five times with phenol/chloroform ( 1:1) and dialyzed at 4°C overnight against 10 mM Tris, pH 7.5, 1 mM EDTA with several changes.
Oligonucleotide primer synthesis. Oligonucleotides for PCR amplification of the four UGTI common exons were synthesized using a Cyclone DNA synthesizer, (model 8400, MilliGen/Biosearch, Bedford, MA) and a 200-coupling 3-phosphoamidite kit (MilliGen/Biosearch).
The oligonucleotides and their sequences are as follows: PXG3, 5'-CTATCTCAAACACGCATGCC-3'; PXG4, 5'-GGATTAGCGCTCC-TGTGAA-3'; PXG5, 5'-GTCTTTCTTTACGTTCTGCTC-3'; PXG6, 5'-GACCCTGGTTTGACCTATAC-3'; PXG7, 5'-CTCAGAGATGT-AACTGCTGAC-3'; PXG8, 5'-CATGAATGCCATGACCAAAG-3'; PXG9, 5'-GTTCATACCACAGGTGTTCCA-3'; PXG 10, 5'-GGAAA-TGACTAGGGAATGGTTC-3';J 127,5'-TCTGAGACCATTGATCC-3'. After synthesis, the oligos were cleaved and deprotected with concentrated aqueous ammonia (29%), as suggested by the manufacturer, dried and resuspended in sterile water, reprecipitated with ethanol, and resuspended in 10 mM Tris, pH 8, and 1 mM EDTA. Oligos were analyzed by electrophoresis through a 12% polyacrylamide gel.
Polymerase chain reaction, subcloning, and sequencing of PCR products. In order to localize mutations in the UGTI locus of CN patients, the polymerase chain reaction (PCR) was performed such that each of the four common exons was amplified in an individual reaction. Nucleotide sequencing ofthe UGTI gene (10) Jolla, CA) prepared using protocol 3 with the rubidium-containing buffers RF1 and RF2 (14) . Ampicillin-resistant transformants were cultured in 7 ml of Luria broth that contained ampicillin (100 Mg/ml), and DNA was purified and sequenced as previously described (15 (16) and recently, from the demonstration of two human bilirubin transferase cDNAs, HUG-Brl and HUG-Br2 (2), which are generated from the UGTI locus (10) . UGTI is a unique gene complex featuring nested transferase transcriptional units (Fig. 1 A) . As demonstrated (10) , each of these units, UGTIA-UGTIF, specifies a unique transferase isoform. The complex contains a tandem array of six promoters ( Fig. 1 A, arrows) with each positioned adjacent to a first exon (Fig. 1 A, (Fig. 1 A, 2-5 ) that are used by all six transcriptional units. Primary messenger RNA transcripts (not shown) are predicted by each unit (10), which undergo differential splicing to produce mature RNAs containing different 5' termini but identical 3' termini ( Fig. 1 B) -2.6 kb in length. Two of these encoded isoforms, UGTIA and UGTID, respectively, represent the transcriptional units that specify mRNAs corresponding to HUG-Brl and HUGBr2 bilirubin transferase cDNAs prepared from mRNA isolated from normal human liver (2) . A third unit, UGTIF, encodes a phenol-specific isoform for which a corresponding cDNA has also been identified (17) . The existence of mRNAs encoded by UGTIBP and UGTIC (but not UGTIE) was confirmed by PCR analysis of a single human liver RNA sample (10) . Because the model predicts that critical mutations introduced into any of the common exons 2-5 will result in the inactivation of all encoded isoforms, we examined these exons for differences in nucleotide sequence.
Identification of 13-bp deletion in exon 2. Exons 2-5 were amplified individually using the PCR and subcloned as described in Methods. Analysis of exon 3, 4, and 5 subclones showed that each had the normal sequence (data not shown). However, a 1 3-bp deletion ( Fig. 1 A, designation of gene location ofdefect by opened arrowhead, and Fig. 2 , details ofdefect) was observed in each ofthe four independent exon 2 subclones. To confirm the mutation, four additional exon 2 subclones were tested from a second PCR reaction, indicating that the mutation was not because of errors by Taq polymerase. The deletion is located 12 bp (downstream) from the intron l-exon 2 junction (Fig. 2) , and causes a change in the deduced amino acid sequence after residue 293 (Fig. 2 A) . 
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(HUG-Br2) 1 The UGT1 locus bilirubin transferase. The deletion ofcodons 294-297 and a -1 frameshift result in the synthesis of truncated forms of both bilirubin transferase isozymes. Fig. 2 A shows the site leading to a change in its predicted translation. The FB sequence would, therefore, be very different from that of a normal individual after codon 294. Continuation of translation of the open reading frame (not shown in Fig. 2 A) shows a TGA stop signal after the 365th codon (illustrated schematically in Fig. 2 B) ; thus, a 72-residue unrelated peptide is present after codon 294. Furthermore, the mutant proteins are predicted to be missing 240 residues of the transferase carboxyl terminal region which is 90% conserved between human and rat. This includes at least two recognized motifs: (a) a highly conserved 18 amino acid sequence (CS, Fig. 2 B) with 2 90% conservation among 11 known transferases (2) brane-anchoring domain (MAD, Fig. 2 B) that permits the retention ofthe transferase protein in the endoplasmic reticulum membrane.
Family genetic analysis. Although it was established by a pedigree study that the parents of F.B. are consanguineous, we demonstrate the pattern of inheritance by F.B. ofthe defective allele. Since CN type I is an autosomal recessive disease, this suggests that F.B. is likely homozygous for the same defective allele, UGTI*FB, and that both parents are heterozygotic at the UGTI*FB locus. This hypothesis was confirmed using the PCR to amplify a fragment corresponding to the last 45 bp of intron 1 and first 154 bp ofexon 2, followed by visualization of the reaction products with agarose gel electrophoresis (Fig. 3) . Whereas a single band ofthe expected normal size (199 bp) was observed in a control sample from an unrelated normal individual (lane 1), the sample corresponding to F.B. (lane 3) contained a single band corresponding to a predicted fragment shorter by 13 bp (186 bp). These observations are consistent with F.B. being homozygous for the allele with a 13-bp deletion. In comparison, the mother (lane 2) and father (lane 4) exhibited both the 199-bp and 1 86-bp bands in equal amounts. Two other slower migrating bands not seen in either the normal or CN type I case were present in the parental samples. A sample representing a reaction that included a mixture of FB and normal DNA (Fig. 3, lane 5) , thereby simulating the composition of heterozygotic DNA, also exhibited these sized bands. These observations are consistent with those from other PCR studies (18) with multiple alleles, which suggest that the bands are caused by mismatched DNA strands (i.e., heteroduplexes), which migrate differently from those that are perfectly matched.
Discussion
Of the hundreds of known substrates that undergo detoxification by glucuronidation (19) , bilirubin was recognized early because of the marked phenotypic changes (jaundice) associated with variable rates in its glucuronidation. Microsomes prepared from the explanted livers ofpatients afflicted with the ultimately fatal disease CN type I do not have detectable bilirubin glucuronidating activity (3), whereas activities towards most substrates are normal (see exceptions below) (20). Here we show that a CN type I patient contains a homozygous 1 3-bp deletion in common exon 2 ofthe gene complex UGTI encoding the two bilirubin transferase proteins. The nature of this defect is consistent with inactivation of the gene product. As deduced by translation of the altered coding region, the bilirubin transferases encoded by UGTJA and UGTJD are predicted to be missing the final 240 amino acids of the wild type proteins, a region which is highly conserved across species (90% identity between rat and human) (2) . This region contains two smaller domains/motifs that have been recognized as highly conserved among deduced transferase sequences including members ofboth major subgroups so far identified, the steroid and bilirubin/phenol subfamilies (21) . A membrane-spanning domain represented by 17 consecutive hydrophobic residues normally flanked on the amino terminal side by a charged residue (Asp) and the carboxyl terminal side by a highly positively charged halt transfer signal (Lys/Arg rich), is located at the extreme carboxyl-terminus of all known transferases. The absence of this region should alter the subcellular localization of the UGTI-encoded proteins. In addition, the highly conserved 18-residue motif overlapping the first six residues ofthe membrane spanning domain and present in all UDP-glucuronosyltransferase isozymes is also missing in FB. [This region was utilized as a strategy for the cloning of the human (2) and rat (22) bilirubin isoforms.] Its function is currently unknown, although it has been speculated that it participates in the binding of the common donor substrate, UDP-glucuronic acid. We have also recently shown (23) that nine amino acids between residues 385-469 in two bile acid/steroid transferase isoforms play a critical role in catalytic efficiency (i.e., whether the transferase is a high-or low-metabolizing isoform).
It should be noted that we cannot exclude the possibility that the deletion of 13 nucleotides from the 132-bp exon 2 causes defective splicing. This prospect seems unlikely since the branchpoint sequence and consensus sequences for splicing appear normal.
In addition to the predicted loss of four codons (294-297), the truncated proteins are predicted to contain a foreign 72-residue carboxyl terminus, resulting from the -1 shift in reading frame. A l-bp deletion with a similar consequence (i.e., the introduction of a premature stop codon) was described at the cDNA levels for phenol and bilirubin transferase mRNAs of the hyperbilirubinemic Gunn rat, considered a model of CN type I disease (24) . Iyanagi et al. (25) showed that defective 3-methylcholanthrene-induction ofphenol glucuronidating activity was due to a -1 frame shift mutation at codon 414 in the mRNA for the phenol form (26) (which is the orthologue ofthe form encoded by the human UGTIF). This mutation results in the synthesis ofa truncated enzyme (27) . More recently, Sato et al. (28) showed that the genetic defect in the bilirubin UDPglucuronosyltransferase mRNA in the Gunn rat was due to the same mutation. These data, together with our recent determination of the UGTJ gene structure, provide an understanding of the complex arrangement ofthe locus and allow the prediction that the other forms encoded within UGTJ are also defective in the CN type I patient studied here, including the isozymes encoded by UGTJBP, UGTJC, and UGTJE. These isoforms may be involved in the glucuronidation ofsubstrates, including phenol (17) , digitoxigenin monodigitoxiside (29), 5-hydroxytryptamine (20, 30), and acetaminophen (31) , that have been associated with the jaundice locus of the rat.
Both CN type I and the hyperbilirubinemia seen in the Gunn rat, are transmitted as autosomal recessive disease entities (7) (8) (9) . In humans, CN type I is a rare disorder which was first described in the literature in 1952 (3), and is often a consequence of consanguineous parents. As for the case described here, the heterozygosity and consanguinity of the parents are the basis of the homozygosity of F.B. at the UGTI*FB locus. Using PCR, we conclusively demonstrated that both parents are carriers of the same defect seen in F.B. Whereas only a shortened band was amplifiable from the DNA of FB, bands of both the deleted size and normal size were amplifiable from that of the parents (Fig. 3) . The PCR assay used in this study may be included as one in a series of diagnostic markersamong others to emerge from future characterization of the different defects associated with heritable hyperbilirubinemic disorders (e.g., CN type II or Gilbert's syndrome).
Although it is not yet known, it is unlikely that a single mutation (UGTI*FB) accounts for all CN type I cases. The existence of multiple phenotypes associated with CN type 1 (9, 32) supports the notion that multiple types of mutations in UGTJ are involved. Furthermore, van Es et al. (20) performed a biochemical and immunochemical analysis of four unrelated CN patients with no detectable transferase activity toward bilirubin. Whereas patients A and B had reduced microsomal transferase activity towards 5-hydroxytryptamine and phenol, patients C and D had normal activities toward these substrates. Furthermore, by using two different monoclonal antibodies (WPl and HEB7) prepared against phenol and bilirubin UDPglucuronosyltransferase, van Es et al. showed that two or more immunostained isozymes were absent in patients A and B, whereas in patients D and C, the polypeptide patterns were similar to controls. These results also suggest a genetic heterogeneity among CN type I patients; some are apparently able to synthesize full length (but presumably inactive) bilirubin transferases, whereas others (such as F.B. described here) synthesize truncated versions. From the results in this study, we are able to predict that microsomes from patient F.B. (who has not undergone liver transplant surgery and therefore has not yet been tested) will exhibit the phenotype which characterized patients A and B. It also suggests the possibility that among CN patients mutations are possible which selectively inactivate one or both of the bilirubin isoforms while sparing the remaining forms encoded by the UGTJ locus (e.g., the UGTJF-encoded phenol form). It is expected that analysis of additional CN patients will uncover a host ofdifferent mutations; with the unique organization of the UGTJ locus, the possibilities abound as to the diversity of mutational sites and their effect(s) on the function ofthis multiple isozyme detoxification system.
